ライフサイエンスコーパス: viral vaccine

1 ollowing nasal delivery of a live attenuated viral vaccine.

2 CMV NAb were produced after two doses of the viral vaccine.

3 induced by the live attenuated yellow fever viral vaccine.

4 bserved upon vaccination with an inactivated viral vaccine.

5 t an excellent candidate for a modified live viral vaccine.

6 platform for creation of live attenuated RNA viral vaccines.

7 of RIG-I ligands as molecular adjuvants for viral vaccines.

8 plausible correlate of attenuation for live viral vaccines.

9 l for monitoring genetic consistency of live viral vaccines.

10 y were used to examine eight live-attenuated viral vaccines.

11 the current safety record of live-attenuated viral vaccines.

12 pesviral gene therapy vectors and attenuated viral vaccines.

13 be an attractive alternative to recombinant viral vaccines.

14 glycosylation patterns in developing subunit viral vaccines.

15 Here, we present a novel viral vaccine adjuvant comprised of two synthetic ligand

16 hnology for development of a live attenuated viral vaccine against dengue viruses.

17 erimental vaccine as a novel live-attenuated viral vaccine against Japanese encephalitis.

18 rational approach to the generation of live viral vaccines: alteration of virally encoded type I IFN

19 ity for improving the safety and efficacy of viral vaccine and oncolytic vectors.

20 ALDI-TOF for routine quality control of live viral vaccines and for assessment of genetic stability a

21 alty applications, such as the production of viral vaccines and gene therapies, reactor technology re

22 ng the safety of chicken RT activity in live viral vaccines and support the continued use of chick-ce

23 the search for an effective live attenuated viral vaccine, and past trials with inactivated virus pr

24 Although egg-based inactivated viral vaccines are available, their effectiveness depend

25 Subunit viral vaccines are typically not as efficient as live at

26 ated YF vaccine is one of the most effective viral vaccines available today.

27 As a first step in creating live attenuated viral vaccine candidates for this serogroup, we have gen

28 tive and dominant-negative HSV-1 recombinant viral vaccine, CJ9-gD, for protection against HSV infect

29 , in circumstances of established tolerance, viral vaccines could break CD8 tolerance in the presence

30 protein trafficking, viral replication, and viral vaccine development.

31 The HA DNA and inactivated viral vaccines elicited similar protection in that initi

32 This viral vaccine, expressing gB derived from CMV strain AD1

33 eactivation in vivo and may be used to study viral vaccines for their ability to establish latency an

34 ponse in mice immunized with the recombinant viral vaccines fowlpox strain FP9 and modified virus Ank

35 Most existing viral vaccines generate antibodies that either block ini

36 Development of new viral vaccines has mostly followed this neutralizing ant

37 the possibility of developing peptide-based viral vaccines having broad coverage across MHC haplotyp

38 L-2 complex) enhances the effectiveness of a viral vaccine in a mouse model with known Ag specificity

39 s of HSV-2 replication-defective recombinant viral vaccines in protection against HSV-2 genital infec

40 Widespread use of bacterial and viral vaccines in young children, including pneumococcal

41 insight into mechanisms by which recombinant viral vaccines induce protective immunity via the MyD88-

42 There is considerable interest in developing viral vaccines intended to induce T cell immunity, espec

43 ation of immune correlates of protection for viral vaccines is complicated by multiple factors, but t

44 nes.IMPORTANCE The genetic stability of live viral vaccines is important for safety and efficacy.

45 ion, several live attenuated and inactivated viral vaccines manufactured in CCLs were approved after

46 etic vaccine systems are less effective than viral vaccines, particularly in cancer systems where epi

47 Although efficacy with multiple viral vaccine platforms has been established in animals,

48 sible, and is similar to that seen for other viral vaccine-preventable diseases.

49 ning GPLN assets to support control of other viral vaccine-preventable, emerging, and reemerging dise

50 y, our data indicate that attenuated or live viral vaccines promote cytokine-induced memory-like NK c

51 Immunization with a killed or inactivated viral vaccine provides significant protection in animals

52 The development of live viral vaccines relies on empirically derived phenotypic

53 ion of revertants during manufacture of live viral vaccines, requiring rigorous quality control to en

54 eld but also to researchers working in other viral vaccine settings and, critically, to the wider fie

55 case illustrates a circumstance when a live viral vaccine should not be used.

56 y of exploiting the RIG-I pathway to enhance viral-vaccine-specific immunity and have broader implica

57 To achieve rational design of viral-vaccine stabilizers, our approach is aided by simp

58 of the top candidates dramatically improved viral vaccine strain production.

59 The first comparison of a live RNA viral vaccine strain to its wild-type parental strain by

60 at could be valuable for the construction of viral vaccine strains against human and animal pathogens

61 elopment of antivirals and shaped cancer and viral vaccine strategies.

62 Recombinant viral vaccines such as those based on vaccinia or adenov

63 eneric and can also be used to predict other viral vaccine targets.

64 c engineering now enables the design of live viral vaccines that are potentially transmissible.

65 ew light on the development of effective HSV viral vaccines that encode a unique safety mechanism cap

66 ding DNA adjuvants to inactivated or subunit viral vaccines that, by themselves, provide only partial

67 ample, in quality control of live attenuated viral vaccines, the presence of even small quantities of

68 field crops, either by the application of a viral vaccine to healthy plants, or by the transgenic ex

69 -1) usually require boosting with protein or viral vaccines to achieve optimal efficacy.

70 Thus, recombinant YF viruses are attractive viral vaccine vector candidates for the development of t

71 some of the most widely used and successful viral vaccine vectors and is also related to the human p

72 sults contrast with those observed for other viral vaccine vectors and suggest that preexisting immun

73 R ligands can modulate the immunogenicity of viral vaccine vectors both positively and negatively.

74 Viral vaccine vectors have emerged as an attractive stra

75 anscriptional competence of live recombinant viral vaccine vectors in the absence of a cold chain.

76 onstrates an important technical advance for viral vaccine vectors progressing to the clinic and prov